(18 September 2023, Athens, Greece) A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence*, a key mechanism of ageing, and the ...

A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...

PARP inhibitors are a drug class that has become an important therapeutic for ovarian and some other cancers. This study looked at pretreatment biopsies to define predictors of response to treatment ...

Researchers at Weill Cornell Medicine have discovered how drugs can affect various membrane-spanning proteins in addition to their intended target, potentially causing unwanted side effects. The ...

In a recent study published in npj Antimicrobials and Resistance, researchers addressed the issue of the rise of antifungal drugs-resistant infections and the advent of multidrug-resistant fungal ...

In a study published in the Journal of Extracellular Vesicles, scientists from the UF Health Cancer Institute have found a way to make treatment for a notoriously aggressive breast cancer more ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.